Cetera Advisors’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $74.9M | Buy |
96,275
+42,003
| +77% | +$29.9M | 0.59% | 21 |
|
|
2023
Q4 | $31.6M | Buy |
54,272
+6,289
| +13% | +$3.67M | 0.44% | 46 |
|
|
2023
Q3 | $25.8M | Buy |
47,983
+2,828
| +6% | +$1.46M | 0.4% | 46 |
|
|
2023
Q2 | $21.2M | Buy |
45,155
+16,329
| +57% | +$6.85M | 0.33% | 64 |
|
|
2023
Q1 | $9.9M | Sell |
28,826
-138
| -0.5% | -$46.5K | 0.16% | 135 |
|
|
2022
Q4 | $10.6M | Buy |
28,964
+10,052
| +53% | +$3.56M | 0.19% | 120 |
|
|
2022
Q3 | $6.12M | Buy |
18,912
+2,163
| +13% | +$685K | 0.16% | 145 |
|
|
2022
Q2 | $5.43M | Buy |
16,749
+1,828
| +12% | +$549K | 0.12% | 170 |
|
|
2022
Q1 | $4.27M | Sell |
14,921
-783
| -5% | -$202K | 0.09% | 246 |
|
|
2021
Q4 | $4.34M | Sell |
15,704
-1,004
| -6% | -$255K | 0.09% | 235 |
|
|
2021
Q3 | $3.86M | Buy |
16,708
+3,322
| +25% | +$820K | 0.08% | 275 |
|
|
2021
Q2 | $3.07M | Buy |
13,386
+444
| +3% | +$89.2K | 0.07% | 272 |
|
|
2021
Q1 | $2.42M | Sell |
12,942
-690
| -5% | -$135K | 0.07% | 279 |
|
|
2020
Q4 | $2.3M | Buy |
13,632
+1,192
| +10% | +$178K | 0.07% | 249 |
|
|
2020
Q3 | $1.84M | Buy |
12,440
+869
| +8% | +$134K | 0.07% | 260 |
|
|
2020
Q2 | $1.9M | Sell |
11,571
-1,767
| -13% | -$271K | 0.08% | 233 |
|
|
2020
Q1 | $1.85M | Buy |
13,338
+2,777
| +26% | +$382K | 0.1% | 208 |
|
|
2019
Q4 | $1.39M | Sell |
10,561
-1,265
| -11% | -$147K | 0.06% | 298 |
|
|
2019
Q3 | $1.32M | Sell |
11,826
-17
| -0.1% | -$1.89K | 0.06% | 296 |
|
|
2019
Q2 | $1.31M | Buy |
11,843
+1,133
| +11% | +$133K | 0.06% | 312 |
|
|
2019
Q1 | $1.39M | Sell |
10,710
-1,056
| -9% | -$128K | 0.07% | 275 |
|
|
2018
Q4 | $1.36M | Sell |
11,766
-927
| -7% | -$104K | 0.08% | 250 |
|
|
2018
Q3 | $1.36M | Buy |
12,693
+1,799
| +17% | +$180K | 0.07% | 278 |
|
|
2018
Q2 | $934K | Sell |
10,894
-415
| -4% | -$34.1K | 0.05% | 338 |
|
|
2018
Q1 | $870K | Sell |
11,309
-206
| -2% | -$16.6K | 0.05% | 340 |
|
|
2017
Q4 | $973K | Sell |
11,515
-48
| -0.4% | -$4.08K | 0.06% | 296 |
|
|
2017
Q3 | $990K | Sell |
11,563
-243
| -2% | -$19.9K | 0.06% | 319 |
|
|
2017
Q2 | $967K | Buy |
11,806
+508
| +4% | +$41.4K | 0.06% | 319 |
|
|
2017
Q1 | $954K | Sell |
11,298
-135
| -1% | -$10.8K | 0.06% | 310 |
|
|
2016
Q4 | $840K | Sell |
11,433
-175
| -2% | -$13K | 0.06% | 311 |
|
|
2016
Q3 | $929K | Sell |
11,608
-1,449
| -11% | -$116K | 0.07% | 283 |
|
|
2016
Q2 | $1.03M | Buy |
13,057
+1,501
| +13% | +$113K | 0.08% | 258 |
|
|
2016
Q1 | $832K | Sell |
11,556
-10,560
| -48% | -$799K | 0.07% | 285 |
|
|
2015
Q4 | $1.87M | Sell |
22,116
-5,139
| -19% | -$426K | 0.16% | 159 |
|
|
2015
Q3 | $2.28M | Buy |
27,255
+1,042
| +4% | +$88K | 0.22% | 120 |
|
|
2015
Q2 | $2.19M | Buy |
26,213
+1,037
| +4% | +$79K | 0.19% | 139 |
|
|
2015
Q1 | $1.83M | Buy |
25,176
+6,590
| +35% | +$469K | 0.17% | 151 |
|
|
2014
Q4 | $1.29M | Buy |
18,586
+2,514
| +16% | +$170K | 0.13% | 198 |
|
|
2014
Q3 | $1.04M | Buy |
16,072
+73
| +0.5% | +$4.62K | 0.08% | 212 |
|
|
2014
Q2 | $987K | Buy |
15,999
+1,489
| +10% | +$88.8K | 0.11% | 219 |
|
|
2014
Q1 | $856K | Buy |
14,510
+9,582
| +194% | +$535K | 0.12% | 198 |
|
|
2013
Q4 | $251K | Buy |
+4,928
| New | +$247K | 0.04% | 413 |
|
Other funds holding LLY
Cetera Advisors's LLY Position: Q1 2024 in Review
Cetera Advisors increased its Eli Lilly (LLY) stake by 77% in Q1 2024, buying an estimated $29.9M and bringing the position to 96,275 shares worth $74.9M. The position accounts for 0.59% of the portfolio, ranked #21.
Cetera Advisors first reported a position in LLY in Q4 2013 and has held it in 42 quarters since. 3,460 funds tracked by Wall St. Rank hold LLY as of Q1 2024.
- Cetera Advisors held 96,275 shares of Eli Lilly worth $74.9M as of Q1 2024.
- Cetera Advisors bought 42,003 Eli Lilly shares in Q1 2024, an estimated $29.9M.
- Eli Lilly made up 0.59% of Cetera Advisors's portfolio in Q1 2024, its #21 holding.
- Cetera Advisors first reported a position in Eli Lilly in Q4 2013 and has held it in 42 quarters since.
- 3,460 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2024.
Based on Cetera Advisors's 13F filing for Q1 2024, filed 15 May 2024.